Table 20. Survival of Patients with CRC PC Treated by CRS and HIPEC and/or EPIC and/or SC: Summary of 76 Researches.
| Author/ Years/ Country | 1-yr SR (%) | 2-yr SR (%) | 3-yr SR (%) | 4-yr SR (%) | 5-yr SR (%) | Mortality Rate (%) |
Morbidity Rate (%) |
Median OS (mo) |
OS 95% CI (mo) |
PFS(95% CI) (mo) | DFS/RFS (95% CI) (mo) |
Follow-up times (range) (mo) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Controlled Studies | ||||||||||||
| Chua TC/ 2009/ Australia [34] | ≈84 | ≈50 | ≈26 | NA | NA | NR | NR | 13 | NR | NR | NR | 18 (9-59) |
| Chua TC/ 2011/ Australia [15] | 92 | NR | 55 | NR | 30 | NR | NR | 38 | 30.2 - 45.2 | NR | 17 (1-216) (two groups) |
17 (1-126) |
| Chua TC/ 2013/ Australia [26] | NR | NR | NR | NR | 41 | NR | NR | 38 | 21.1 - 54.9 | NR | 33 (22.4-43.8) (RFS) |
22 (5-88) |
| Elias D/ 2001/ France [35] | NR | ≈70 | ≈53 | ≈53 | ≈44 | 8.1 | Overall: 54.6 | ≈54 | NR | NR | ≈26 2-,3-,5-yr 54.7%, 39.4% and 18.4% (two groups) |
51.7 (8.1-89.3) |
| Elias D/ 2007/ France [36] | ≈96 | ≈78 | ≈63 | ≈54 | 54 | 0 | 4 | NA | NR | NR | NR | 113 (70-188) |
| Elias D/ 2009/ France [28] | NR | 81 | NR | NR | 51 | NR | NR | 62.7 | NR | NR | NR | 95.7 vs. 63 |
| Elias D/ 2010/ France [14] | NR | NR | 40 | NR | 25.5 | NR | NR | 31 | NR | NR | ≈9 1-,3-,5-yr 47%, 15% and 10% (two groups) |
NR |
| Esquivel J/ 2014/ America [29] | NR | NR | 66 | NR | 58 | NR | NR | 41 | 38.0-46.3 | NR | NR | 25 vs. 8 (0.1-128) |
| Franko J/ 2010/ America [37] | ≈92 | ≈66 | ≈51 | ≈44 | ≈28 | NR | NR | 34.7 | NR | NR | NR | NR |
| Gervais MK/ 2013/ Canada [38] | ≈92 | ≈76 | 61 | ≈53 | 36 | 4 | 20 | ≈54 | NR | NR | ≈8 | 22.8 (2-81) |
| Glehen O/ 2004/ France [13] | NR | NR | NR | NR | NR | NR | NR | 21.6/19.2 | NR | NR | NR | 53 (5-192) |
| Goéré D/ 2015/ France [99] | ≈90 | ≈72 | 52 | ≈40 | ≈32 | 5.8 | 29.5 | ≈35 | NR | NR | NR | 60 (47-74) |
| Huang CQ/ 2014/ China [39] | 63.6 | 20.0 | 16.0 | NR | NR | 0 | 28.6 | 13.7 | 10.0-16.5 | NR | NR | 41.5 (11.5-70.9) |
| Passot G/ 2014/ France [40] | NR | NR | NR | NR | NR | NR | NR | 36 | NR | NR | NR | NR |
| Verwaal VJ/ 2003/ Netherlands [12] | ≈66 | ≈42 | ≈32 | NR | NR | 8 | 19 | 22.4 | NR | NR | NR | 21.6 |
| Subtotal of 15 studies (Mean ± SD; Median/Range) |
84.5 ± 12.6 vs. 58.1 ± 20.6 91 (63.6-96) vs. 54 (27.5-87) |
61.7 ± 20.3 vs. 38.8 ± 18.7 70 (20-81) vs. 42 (12-65) |
46.8 ± 16.2 vs. 23.6 ± 15.2 52 (16-66) vs. 18 (0-47) |
48.8 ± 6.4 vs. 20.4 ± 10.1 53 (44-54) vs. 22 (14-33) |
40.0 ± 11.5 vs. 18.1 ± 14.1 38 (25.5-58) vs. 18 (0-44) |
4.3 ± 3.7 vs. 6.2 ± 4.2 5 (0-8.1) vs. 6.3 (0-11.1) |
19.8 ± 9.2 vs. 20.5 ± 12.3 19.5 (4-29.5) vs. 23 (3.1-31.6) |
34.3 ± 14.8 vs. 18.8 ± 8.8 35 (13-62.7) vs. 17 (8.5-34) |
43.8 ± 32.8 vs. 29.7 ± 29.3 25 (17-113) vs. 18 (8-63) |
|||
Note: yr: year; SR: survival rate; mo: months; OS: overall survival; PFS: progression-free survival; RFS: recurrence-free survival; DFS: disease-free survival; NA: not achieved; NR: not reported; PMP: pseudomyxoma peritonei; L-OHP: oxaliplatin; MMC: mitomycin; all: all tumors in researches; MVR: multivisceral resection group; NVR: No visceral resection group; APP: appendix; NNT: non-neoadjuvant therapy; NCA: neoadjuvant chemotherapy alone; NCB: neoadjuvant chemotherapy + bevacizumab; AC: adjuvant chemotherapy; NAC: non- adjuvant chemotherapy